Türkiyefa Afyon MustaMikrobiyoloji ve Klinik Mikrobiyoloji Ana BD. ALTINDİŞ, Birol ŞAFAK, Tuna DEMİRDAL, Zafer ÇETİNKAYA, Orhan Cem AKTEPE

Kan kültürlerinden izole edilen etkenlerde tigesiklin duyarlılığı

Kan kültürlerinden Ocak-Ekim 2006 döneminde izole edilen ve infeksiyon etkeni olarak kabul edilen 70 bakteriye tigesiklinin etkinliği potansiyel ampirik ajanların in-vitro etkinlikleri ile karşılaştırılmıştır. Bakterilerin 28’i GSBL pozitif Escherichia coli, 19’u MRSA, 9’u Enterococcus spp., 7’si Klebsiella spp., 6’sı Enterobacter spp., 1’i S.pneumoniae olarak identifiye edilmiştir. Tüm izolatlar otomatize Phoenix system (BD Diagnostic Systems) ile tanımlanmıştır. Tigesiklinin MİK değerleri CLSI kriterlerine uygun olarak Mueller Hinton agarda E test yöntemi ile belirlenmiş ve bütün suşlar duyarlı bulunmuştur. Ayrıca her izolat için Kirby-Bauer disk difüzyon metoduyla piperasilin-tazobaktam, siprofloksasin, tetrasiklin ve imipenem duyarlılığı test edilmiştir. Anılan patojenler üzerine, piperasilin-tazobaktam, imipenem, siprofloksasin ve tetrasiklinin in-vitro etkinlikleri ile karşılaştırıldığında tigesiklinin daha etkin olduğu gözlenmiştir. Sonuç olarak tigesiklin çalışmaya alınan mikroorganizmaların tümüne karşı etkili bir antimikrobiyal olarak bulunmuştur.

Anahtar Kelimeler:

Serum bakterisit testi, Çapraz enfeksiyon, İlaç direnci, bakteriyel, Mikrobiyal duyarlılık testleri

PDF

___

1. Betriu C, Rodriguez-Avial I, Gomez M et al and Spanish Tigecycline Group: Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study, Diagn Microbiol Infect Dis 2006;56(4):437-44.

2. Bouchillon SK, Hoban DJ, Johnson BM, Johnson JL, Hsiung A, Dowzicky MJ and Tigecycline Evaluation and Surveillance Trial (TEST) Group: In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004), Diagn Microbiol Infect Dis 2005;52(3):173-9.

3. Dipersio JR, Dowzicky MJ: Regional variations in multidrug resistance among Enterobacteriaceae in the USA and comparative activity of tigecycline, a new glycylcycline antimicrobial, Int J Antimicrob Agents 2007:29(5):518-27.

4. Gales AC, Jones RN, Andrade SS, Pereira AS, Sader HS: In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America, Braz J Infect Dis 2005;9(5):348-56.

5. Hawkey P, Finch R: Tigecycline: in-vitro performance as a predictor of clinical efficacy, Clin Microbiol Infect 2007;13(4):354-62.

6. Morosini MI, Garcia-Castillo M, Coque TM et al: Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline, Antimicrob Agents Chemother 2006;50(8):2695-9.

7. Nathwani D: Tigecycline: clinical evidence and formulary positioning, Int J Antimicrob Agents 2005;25(3):185-92.

8. Pankey GA: Tigecycline, J Antimicrob Chemother 2005;56(3):470-80.

9. Sader HS, Jones RN, Dowzicky MJ, Fritsche TR: Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit, Diagn Microbiol Infect Dis 2005;52(3):203-8.

10. Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR: Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents, Diagn Microbiol Infect Dis 2005;52(3):181-6.

11. Souli M, Kontopidou FV, Koratzanis E et al: In vitro activity of tigecycline against multiple-drugresistant, including pan-resistant, Gram-negative and Gram-positive clinical isolates from Greek hospitals, Antimicrob Agents Chemother 2006;50(9):3166-9.

12. Stein GE, Craig WA: Tigecycline: a critical analysis, Clin Infect Dis 2006;43(4):518-24.

13. Townsend ML, Pound MW, Drew RH: Tigecycline: A new glycylcycline antimicrobial, Int J Clin Pract 2006;60(12):1662-72.

14. Ulusoy S: Tigesiklin, ANKEM Derg 2006;20(Ek 2):117-9.

15. Waites KB, Duffy LB, Dowzicky MJ: Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial, Antimicrob Agents Chemother 2006;50(10):3479-84.